Swiss Medica, Inc.
OTC Bulletin Board : SWME

Swiss Medica, Inc.

August 09, 2005 06:01 ET

CVS/Pharmacy Now Offering Swiss Medica's PMS Escape Product

TORONTO, ONTARIO--(CCNMatthews - Aug. 9, 2005) - Swiss Medica, Inc. (OTCBB:SWME) is pleased to announce that CVS/Pharmacy is now offering the PMS Escape product nationwide.

"We are excited CVS/pharmacy has become our first U.S. national pharmacy chain to carry PMS Escape," said Wendy Kramer, Swiss Medica's Vice President. "We believe this will offer millions of women the opportunity to purchase PMS Escape - a clinically studied, patented, safe and effective product for the normal mood and appetite symptoms associated with premenstrual syndrome."

About Swiss Medica, Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at www.swissmedica.com, www.O24zone.com and www.pmsescape.com.

Swiss Medica's flagship product, the O24™ Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24™ pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by healthcare professionals in the United States, Canada and in Europe. O24 is widely available throughout Canada in leading pharmacies and natural food stores. It is currently sold in an increasing number of pharmacies throughout the United States. Customers can also visit www.O24zone.com, for ordering details and store locators for the nearest pharmacy.

Swiss Medica also manufactures PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit: www.pmsescape.com for additional information and ordering details.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Swiss Medica, Inc.
    Investor Relations Contact:
    David Jones
    (866) 485-4243
    or
    Cone Communications
    Public Relations Contact:
    Stephanie Doherty
    (617) 227-2111
    sdoherty@coneinc.com
    or
    Stern & Co.
    Financial Media Contact:
    Stan Froelich, VP, Media Relations
    (212) 888-0044
    sfroelich@sternco.com